Molecular characterization of cefoxitin-resistant Escherichia coli from Canadian hospitals

Antimicrobial Agents and Chemotherapy

Volumn 49, Issue 1, 2005, Pages 358-365

  Mulvey, Michael R ^a   Bryce, Elizabeth ^c   Boyd, David A ^a   Ofner Agostini, Marianna ^d   Land, Allison M ^a   Simor, Andrew E ^e   Paton, Shirley ^b  

^a PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^b PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^c VANCOUVER GENERAL HOSPITAL   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; BETA LACTAMASE; CEFAZOLIN; CEFOTETAN; CEFOXITIN; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; COTRIMOXAZOLE; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; NITROFURANTOIN; PIPERACILLIN PLUS TAZOBACTAM; TOBRAMYCIN;

ADULT; AGED; AMPC GENE; ANTIBIOTIC RESISTANCE; ARTICLE; ATTENUATION; BACTERIAL MUTATION; BACTERIUM ISOLATION; CANADA; ESCHERICHIA COLI; FEMALE; GENE; GENE INSERTION; GENETIC SCREENING; HOSPITAL CARE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOLECULAR BIOLOGY; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; PULSED FIELD GEL ELECTROPHORESIS; SENSITIVITY ANALYSIS; SEQUENCE ANALYSIS; STATISTICAL SIGNIFICANCE; STRAIN IDENTIFICATION; WILD TYPE;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BASE SEQUENCE; BETA-LACTAMASES; CANADA; CEFOXITIN; CEPHALOSPORIN RESISTANCE; ELECTROPHORESIS, GEL, PULSED-FIELD; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; HOSPITALS; HUMANS; MICROBIAL SENSITIVITY TESTS; MOLECULAR SEQUENCE DATA; MUTATION; POPULATION SURVEILLANCE; PROMOTER REGIONS (GENETICS); PROSPECTIVE STUDIES; SEQUENCE ANALYSIS, DNA;

EID: 11244344839     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.49.1.358-365.2005     Document Type: Article

References (34)

1. Allen, K. J., and C. Poppe. 2002. Occurrence and characterization of resistance to extended-spectrum cephalosporins mediated by β-lactamase CMY-2 in Salmonella isolated from food-producing animals in Canada. Can. J. Vet. Res. 66:137-144.
2. Alvarez, M., J. H. Tran, N. Chow, and G. A. Jacoby. 2004. Epidemiology of conjugative plasmid-mediated AmpC β-lactamases in the United States. Antimicrob. Agents Chemother. 48:533-537.
3. Briñas, L., M. Zarazaga, Y. Sáenz, F. Ruiz-Laerra, and C. Torres. 2002. β-Lactamases in ampicillin-resistant Escherichia coli isolates from foods, humans, and healthy animals. Antimicrob. Agents Chemother. 46:3156-3163.
4. Caroff, N., E. Espaze, I. Berard, H. Richet, and A. Reynaud. 1999. Mutations in the ampC promoter of Escherichia coli isolates resistant to oxyiminocephalosporins without extended spectrum β-lactamase production. FEMS Microbiol. Lett. 173:459-465.
5. Caroff, N., E. Espaze, D. Gautreau, H. Richet, and A. Reynaud. 2000. Analysis of the effects of -42 and -32 ampC promoter mutations in clinical isolates of Escherichia coli hyperproducing AmpC. J. Antimicrob. Chemother. 45:783-788.
6. Centers for Disease Control and Prevention. 2002. Outbreak of multidrug-resistant Salmonella Newport - United States, January-April 2002. Morb. Mortal. Wkly. Rep. 51:545-548.
7. Corvec, S., N. Caroff, E. Espaze, J. Marraillac, and A. Reynaud. 2002. -11 mutation in the ampC promoter increasing resistance to β-lactams in a clinical Escherichia coli strain. Antimicrob. Agents Chemother. 46:3265-3267.
8. Corvec, S., N. Caroff, E. Espaze, C. Giraudeau, H. Drugeon, and A. Reynaud. 2003. AmpC cephalosporinase hyperproduction in Acinetobacter baumannii clinical strains. J. Antimicrob. Chemother. 52:629-635.
9. Dunne, E. F., P. D. Fey, P. Kludt, R. Reporter, F. Mostashari, P. Shillam, J. Wicklund, C. Miller, B. Holland, K. Stamey, T. J. Barrett, J. K. Rasheed, F. C. Tenover, E. M. Ribot, and F. J. Angulo. 2000. Emergence of domestically acquired ceftriaxone-resistant Salmonella infections associated with ampC beta-lactamase. JAMA 284:3151-3156.
10. Forward, K. R., B. M. Willey, D. E. Low, A. McGeer, M. A. Kapala, M. M. Kapala, and L. L. Burrows. 2001. Molecular mechanisms of cefoxitin resistance in Escherichia coli from Toronto area hospitals. Diagn. Microbiol. Infect. Dis. 41:57-63.
11. Hanson, N. D. 2003. AmpC beta-lactamases: what do we need to know for the future? J. Antimicrob. Chemother. 52:2-4.
12. Hawley, D. K., and W. R. McClure. 1983. Compilation and analysis of Escherichia coli promoter DNA sequences. Nucleic Acids Res. 11:2237-2255.
13. Jaurin, B., T. Grundström, T. Edlund, and S. Normark. 1981. The E. coli β-lactamase attenuator mediates growth rate-dependent regulation. Nature 290:221-225.
14. Jaurin, B., T. Grundström, and S. Normark. 1982. Sequence elements determining ampC promoter strength in E. coli. EMBO J. 1:875-881.
15. Jaurin, B., and S. Normark. 1983. Insertion of IS2 creates a novel ampC promoter in Escherichia coli. Cell 32:809-816.
16. Mulvey, M. R., E. Bryce, D. Boyd, M. Ofner-Agostini, S. Christianson, A. E. Simor, S. Paton, and The Canadian Hospital Epidemiology Committee of the Canadian Nosocomial Infection Surveillance Program, Health Canada. 2004. Ambler class A extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. in Canadian hospitals. Antimicrob. Agents Chemother. 48:1204-1214.
17. National Committee for Clinical Laboratory Standards. 2000. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 5th ed. Approved standard M7-A4. National Committee for Clinical Laboratory Standards, Wayne, Pa.
18. National Committee for Clinical Laboratory Standards. 2000. Methods for disk susceptibility tests for bacteria that grow aerobically, 7th ed. Approved standard M2-A7. National Committee for Clinical Laboratory Standards, Wayne, Pa.
19. National Committee for Clinical Laboratory Standards. 2003. Performance standards for disk susceptibility tests, 8th ed. Approved standard M2-A8. National Committee for Clinical Laboratory Standards, Wayne, Pa.
20. Nelson, E. C., and B. G. Elisha. 1999. Molecular basis of AmpC hyperproduction in clinical isolates of Escherichia coli. Antimicrob. Agents Chemother. 43:957-959.
21. Olsson, O., S. Bergström, and S. Normark. 1982. Identification of a novel ampC β-lactamase promoter in a clinical isolate of Escherichia coli. EMBO J. 1:1411-1416.
22. Olsson, O., S. Bergström, F. P. Lindberg, and S. Normark. 1983. ampC β-lactamase hyperproduction in Escherichia coli: natural ampicillin resistance generated by horizontal chromosomal DNA transfer from Shigella. Proc. Natl. Acad. Sci. USA 80:7556-7560.
23. Papanicolaou, G. A., A. A. Medeiros, and G. A. Jacoby. 1990. Novel plasmid-mediated β-lactamase (MIR-1) conferring resistance to oxyimino- and α-methoxy β-lactams in clinical isolates of Klebsiella pneumoniae. Antimicrob. Agents Chemother. 34:2200-2209.
24. Pérez-Pérez, F. J., and N. D. Hanson. 2002. Detection of plasmid-mediated AmpC beta-lactamase genes in clinical isolates by using multiplex PCR. J. Clin. Microbiol. 40:2153-2162.
25. Philippon, A., G. Arlet, and G. A. Jacoby. 2002. Plasmid-determined AmpC-type β-lactamases. Antimicrob. Agents Chemother. 46:1-11.
26. Pitout, J. D. D., M. D. Reisbig, M. Mulvey, L. Chui, M. Louie, L. Crowe, D. L. Church, S. Elsayedd, D. Gregson, R. Ahmed, P. Tilley, and N. D. Hanson. 2003. Association between handling of pet treats and infection with Salmonella enterica serotype Newport expressing the AmpC β-lactamase, CMY-2. J. Clin. Microbiol. 41:4578-4582.
27. Randegger, C. C., A. Keller, M. Irla, A. Wada, and H. Hächler. 2000. Contribution of natural amino acid substitutions in SHV extended-spectrum β-lactamases to resistance against various β-lactams. Antimicrob. Agents Chemother. 44:2759-2763.
28. Simons, R. W., B. C. Hoopes, W. R. McClure, and N. Kleckner. 1983. Three promoters near the termini of IS10: pIN, pOUT, and pIII. Cell 34:673-682.
29. Siu, L. K., P.-L. Lu, J.-Y. Chen, F. M. Lin, and S.-C. Chang. 2003. High level expression of AmpC β-lactamase due to insertion of nucleotides between -10 and -35 promoter sequences in Escherichia coli clinical isolates: cases not responsive to extended-spectrum cephalosporin treatment. Antimicrob. Agents Chemother. 47:2138-2144.
30. Swaminathan, B., T. Barrett, S. B. Hunter, and R. Tauxe. 2001. PulseNet: the molecular subtyping network for foodborne disease surveillance in the United States. Emerg. Infect. Dis. 7:382-389.
31. Thomson, K. S. 2001. Controversies about extended spectrum and AmpC beta-lactamases. Emerg. Infect. Dis. 7:333-336.
32. Winokur, P. L., A. Bruggemann, D. L. DeSalvo, L. Hoffmann, M. D. Apley, E. K. Uhlenhopp, M. A. Pfaller, and G. V. Doern. 2000. Animal and human multidrug-resistant, cephalosporin-resistant Salmonella isolates expressing a plasmid-mediated CMY-2 AmpC β-lactamase. Antimicrob. Agents Chemother. 44:2777-2783.
33. Winokur, P. L., D. L. Vonstein, L. J. Hoffman, E. K. Uhlenhopp, and G. V. Doern. 2001. Evidence for transfer of CMY-2 AmpC β-lactamase plasmids between Escherichia coli and Salmonella isolates from food animals and humans. Antimicrob. Agents Chemother. 45:2716-2722.
34. Zhao, S., S. Qaiyumi, S. Friedman, R. Singh, S. L. Foley, D. G. White, P. F. McDermott, T. Donkar, C. Bolin, S. Munro, E. J. Baron, and R. D. Walker. 2003. Characterization of Salmonella enterica serotype Newport isolated from humans and food animals. J. Clin. Microbiol. 41:5366-5371.